Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
TPST Stock Chart & Stats
$2.28
$0.02(2.27%)
At close: 4:00 PM EST
$2.28
$0.02(2.27%)
Day’s Range― - ―
52-Week Range$2.12 - $12.23
Previous CloseN/A
Volume2.28M
Average Volume (3M)50.79K
Market Cap
$30.74M
Enterprise Value$12.12M
Total Cash (Recent Filing)$7.51M
Total Debt (Recent Filing)$8.40M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Apr 01, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding13,481,070
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)15.83
Price to Sales (P/S)0.00
P/FCF Ratio-9.05
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-91.16
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$11.00Price Target Upside382.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-16.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayExtended cash runway from the transaction provides capital to advance the new lead program through initial clinical milestones without immediate fundraising pressure.
Clinical DataPositive early clinical results for TPST-2003, a clinically de‑risked dual‑target CAR‑T, strengthen the program's development profile and increase attractiveness for potential partners or accelerated development paths.
Regulatory And Market StrategyTwo distinct value pathways—a potentially faster regulatory route in China and a differentiated U.S. strategy focused on extramedullary relapsed/refractory multiple myeloma—expand commercialization options and strategic flexibility.
Bears Say
Financing And Partnership RiskLegacy programs will require additional financing or partnerships to progress, creating reliance on external capital or collaborators and increasing execution risk for those assets.
Legacy Pipeline DeprioritizationDeprioritization of legacy oncology programs, including amezalpat and TPST-1495, reduces near‑term upside from those assets and narrows the company's therapeutic breadth.
Shareholder DilutionExisting shareholders lose majority ownership in the combined company and face substantial dilution from the transaction structure, which may weaken investor influence and sentiment.
Tempest Therapeutics News
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $2.12 and its highest was $12.23 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $30.74M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 31 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$3.27 by $2.48.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.62.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 13,481,070 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$3.27. Following the earnings report the stock price went up 9.101%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempest Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (382.46% Upside)
$11.00 (382.46% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.36%
12-Months-Change
Fundamentals
Return on Equity
-405.03%
Trailing 12-Months
Asset Growth
-41.94%
Trailing 12-Months
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
TPST Stock 12 Month Forecast
Average Price Target
$11.00
▲(382.46% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.29% Mutual Funds
0.08% Other Institutional Investors
97.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---